COMPASS Pathways (NASDAQ:CMPS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Zacks reports.
COMPASS Pathways Stock Down 6.6 %
NASDAQ CMPS traded down $0.26 on Monday, reaching $3.67. The company had a trading volume of 1,256,018 shares, compared to its average volume of 1,272,663. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The company's fifty day moving average is $4.06 and its 200 day moving average is $5.23. COMPASS Pathways has a 52-week low of $3.16 and a 52-week high of $12.57. The stock has a market capitalization of $251.11 million, a P/E ratio of -1.67 and a beta of 2.28.
Analyst Ratings Changes
A number of brokerages have recently commented on CMPS. HC Wainwright cut their price target on shares of COMPASS Pathways from $60.00 to $45.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. Canaccord Genuity Group cut their price target on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday. Finally, Stifel Nicolaus assumed coverage on COMPASS Pathways in a research note on Thursday. They set a "buy" rating and a $11.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, COMPASS Pathways has an average rating of "Buy" and an average target price of $21.83.
View Our Latest Stock Report on COMPASS Pathways
About COMPASS Pathways
(
Get Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Featured Articles
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
